Moderna's Seasonal mRNA Flu Vaccine Faces Setback from FDA Review

The FDA has declined to review Moderna's request for its first seasonal mRNA flu vaccine, citing inadequate clinical trial controls. This decision, communicated in a letter dated February 3, indicates that the control group did not meet the best standard of care available in the U.S. at the time of the study. Despite no safety or efficacy concerns being raised, Moderna expressed surprise at the FDA's reversal, especially after previous agreements on the trial's design. The company is now seeking a meeting with FDA officials to clarify the next steps. The setback comes as Moderna aims to integrate mRNA technology into flu vaccines, hoping to enhance effectiveness and streamline production.

Key Details: • FDA's decision letter dated February 3, 2024. • Moderna's clinical trial involved 40,700 participants. • The company plans to discuss next steps with the FDA following the rejection. • Moderna is also developing a combined flu and COVID-19 mRNA vaccine, which is on hold pending FDA guidance.